Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing **esomeprazole**, a proton pump inhibitor (PPI), and **amoxicillin** and **clarithromycin**, antibiotics. This formulation is designed for the eradication of *Helicobacter pylori*.
## Primary Indications
* Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
* **Sompraz HP (20 mg esomeprazole/1000 mg amoxicillin/500 mg clarithromycin) - 1 capsule orally twice daily for 10 days.**
* The dosing is typically one capsule in the morning and one capsule in the evening for 10 days.
## Pediatric Dosing
* Pediatric dosing is not established for Sompraz HP. Treatment regimens for *H. pylori* in children should be guided by specialist recommendations and may involve different formulations or doses of individual components.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment for esomeprazole, amoxicillin, or clarithromycin is typically required in mild to moderate renal impairment. Severe renal impairment may necessitate caution and potential dose adjustment of amoxicillin, though specific guidance for this combination product is limited.
* **Hepatic Impairment:** In severe hepatic impairment, the dose of esomeprazole should be reduced. Standard adult doses of amoxicillin and clarithromycin are generally used in hepatic impairment, but caution is advised.
## Contraindications
* Hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of hypersensitivity to other beta-lactam antibacterials (e.g., penicillin, cephalosporins) or macrolides.
* Concomitant use with ergotamine or dihydroergotamine due to potential for ergotism.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Patients with certain cardiac conditions (e.g., QTc prolongation, significant electrolyte abnormalities, bradycardia, arrhythmias) due to clarithromycin's potential effects.
* Electrolyte disturbances (hypokalemia, hypomagnesemia).
## Adverse Effects
* **Common:** Diarrhea, nausea, abdominal pain, taste disturbances, headache, rash.
* **Serious:** *Clostridioides difficile*-associated diarrhea, severe hypersensitivity reactions (including anaphylaxis), *Stevens-Johnson syndrome*, toxic epidermal necrolysis, liver dysfunction, QT prolongation, *C. pylori*-resistant strains.
## Key Drug Interactions
* **Clarithromycin:**
* CYP3A4 inhibitors/inducers: May alter levels of drugs metabolized by CYP3A4 (e.g., statins, calcium channel blockers, anticoagulants).
* Colchicine: Increased colchicine levels, potentially life-threatening.
* Digoxin: Increased digoxin levels.
* Warfarin: May potentiate anticoagulant effects.
* **Esomeprazole:**
* CYP2C19 and CYP3A4 substrates: May increase levels of drugs like clopidogrel, methotrexate, diazepam, phenytoin.
* Ketoconazole, itraconazole, posaconazole: Decreased absorption due to increased gastric pH.
* **Amoxicillin:**
* Allopurinol: Increased incidence of rash.
* Probenecid: Decreased renal excretion of amoxicillin.
* Oral contraceptives: May decrease efficacy.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Assess for diarrhea and rule out *C. difficile*-associated diarrhea.
* Monitor liver function tests, especially with prolonged use or in patients with hepatic impairment.
* Evaluate for development of *H. pylori* resistance.
* Assess for therapeutic response (symptom improvement, ulcer healing).
## Clinical Pearls
* This combination is designed for patient convenience and adherence by providing all necessary medications in a single regimen.
* Ensure patients complete the full 10-day course of therapy, even if they feel better, to ensure eradication of *H. pylori* and prevent resistance.
* Advise patients to take the medication as prescribed, typically one capsule in the morning and one in the evening.
* Consider potential for cross-reactivity with penicillin allergies when prescribing amoxicillin.
* Be aware of the risk of developing clarithromycin resistance, which can impact future treatment success.
***
**Disclaimer:** This information is intended for healthcare professionals. Please consult the official prescribing information and current clinical guidelines for the most up-to-date and comprehensive drug information. Local protocols may vary.
